BIOMAT Database Logo BIOMAT Database Logo

ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages. 1984

C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato

The effects of medroxyprogesterone acetate (MPA) at high dosages on ACTH and cortisol plasma levels have been studied on seven patients which were carriers of ER+ and PR+ neoplasm. ACTH and cortisol plasma levels were studied at 8:00 a.m., before and after a 4-week treatment with MPA at dosages of 1000 mg/die at basal conditions and after a metyrapone stimulation test. The results obtained show that the MPA treatment causes a highly significant drop of both cortisol and ACTH plasma levels. The metyrapone stimulation test performed before and after MPA treatment confirms the suppressive effect of MPA on the hypothalamus-pituitary-adrenal gland axis. These data suggest a cortisol-like action of MPA with a negative feed-back mechanism on the hypothalamus-pituitary-adrenal gland axis.

UI MeSH Term Description Entries
D008297 Male Males
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic

Related Publications

C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
[Evolution of plasma somatotropin levels in acromegaly treated with medroxyprogesterone acetate].
January 1973, Annales d'endocrinologie,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Plasma ACTH and cortisol levels in benzodiazepine treated rats.
February 1980, Pharmacological research communications,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
January 1983, Cancer chemotherapy and pharmacology,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
January 1985, Cancer treatment reports,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Plasma Cortisol Levels in Patients Treated Extensively with Fluprednylidene-21 Acetate Topical Cream (decoderm).
January 1977, Indian journal of dermatology, venereology and leprology,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer.
March 1990, British journal of urology,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Variable response of plasma GH in acromegalic patients treated with medroxyprogesterone acetate.
September 1971, The Journal of clinical endocrinology and metabolism,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Variable response of plasma GH in acromegalic patients treated with medroxyprogesterone acetate.
September 1971, The Journal of clinical endocrinology,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients.
January 1982, Cancer chemotherapy and pharmacology,
C Papaleo, and C Carella, and G A Zito, and A Figlia, and F Capuano, and G Amato
Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
December 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Copied contents to your clipboard!